All Cosmos Bio-Tech Holding Corp. AI Stock Analysis
All Cosmos Bio-Tech Holding Corp. (4148) AI Stock Analysis
All Cosmos Bio-Tech Holding Corp.
(TWSE:4148)
All Cosmos Bio-Tech scores moderately. The main support comes from a solid financial position: a conservative balance sheet with very low leverage, a 20% revenue rebound, margin expansion and a return to positive free cash flow. Valuation adds to the case, with a P/E near 10 and a 3.6% dividend yield. Offsetting these strengths, the share price is in a clear downtrend below all key moving averages with negative MACD momentum, and the business has a history of volatile revenue, earnings and cash flow, with return on equity and net margin still well below 2022 levels. The result is a fundamentally sound but cyclically inconsistent company currently out of favour with the market.
All Cosmos Bio-Tech Holding Corp. (4148) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.97B
- Dividend Yield
- 3.42%
- Average Volume (3M)
- 47.56K
- Price to Earnings (P/E)
- 10.8
- Beta (1Y)
- 0.15
- Revenue Growth
- 15.66%
- EPS Growth
- 31.51%
- Country
- TW
- Employees
- 368
- Sector
- General
- Sector Strength
- 55
- Industry
- Agricultural Inputs
All Cosmos Bio-Tech Holding Corp. Business Overview & Revenue Model
Company Description
All Cosmos Bio-Tech Holding Corporation, through its various operating units, primarily focuses on the production and distribution of bio-organic and bio-chemical compound fertilizers across Malaysia. The company also dedicates efforts to the researc...
All Cosmos Bio-Tech Holding Corp. Financial Statement Overview
Summary
A recovery year supported by a conservative balance sheet. Revenue rose about 20% to roughly NT$2.95 billion, gross margin widened to 28.1%, operating profit nearly doubled to NT$297 million, and net income increased about 19% to NT$153 million (Income Statement 61). The balance sheet is the standout (73), with debt-to-equity near 0.14 and equity funding about 65% of assets, though return on equity of just 5.6% is well below the 15.6% achieved in 2022. Cash flow (58) improved sharply, with operating cash flow of about NT$252 million and free cash flow turning positive at roughly NT$209 million, but free cash flow was negative in three of the past five years and operating cash flow has swung wildly. Net margin of about 5.2% remains flat for three years and far below the 2022 peak, so earnings consistency is still unproven.
Income Statement
61PositiveBalance Sheet
73PositiveCash Flow
58Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.17B | 2.95B | 2.46B | 2.83B | 3.70B | 2.20B |
| Gross Profit | 897.64M | 829.47M | 668.59M | 587.98M | 1.14B | 594.37M |
| EBITDA | 394.27M | 362.56M | 312.83M | 310.76M | 699.84M | 373.03M |
| Net Income | 185.78M | 153.00M | 128.59M | 139.36M | 368.20M | 198.13M |
Balance Sheet | ||||||
| Total Assets | 4.55B | 4.22B | 3.67B | 3.67B | 4.11B | 2.97B |
| Cash, Cash Equivalents and Short-Term Investments | 1.42B | 1.44B | 1.25B | 1.66B | 1.47B | 930.13M |
| Total Debt | 612.75M | 381.29M | 261.61M | 543.09M | 942.46M | 311.31M |
| Total Liabilities | 1.04B | 779.83M | 540.27M | 859.54M | 1.25B | 591.28M |
| Stockholders Equity | 2.77B | 2.74B | 2.52B | 2.25B | 2.37B | 1.99B |
Cash Flow | ||||||
| Free Cash Flow | 186.53M | 209.08M | -88.06M | 795.82M | -17.02M | -171.49M |
| Operating Cash Flow | 219.52M | 251.93M | 54.19M | 959.24M | 43.84M | -67.64M |
| Investing Cash Flow | -294.23M | -277.80M | -228.46M | -202.98M | -4.67M | -108.17M |
| Financing Cash Flow | 58.61M | 82.94M | -428.49M | -549.88M | 490.39M | 196.10M |
All Cosmos Bio-Tech Holding Corp. Peers Comparison
Overall Rating
TW:491172Outperform
TW:698667Neutral- TW:414860Neutral
TW:129559Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4911 | 72Outperform | TWD 1.74B | 18.88 | ― | 4.61% | -26.73% | -34.96% |
| TW:6986 | 67Neutral | TWD 1.94B | 14.13 | ― | 0.52% | ― | ― |
| TW:4148 | 60Neutral | TWD 1.96B | 10.80 | ― | 3.42% | 15.66% | 31.51% |
| TW:1295 | 59Neutral | TWD 1.57B | 10.01 | ― | 7.16% | -5.28% | -27.33% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4148 | All Cosmos Bio-Tech Holding Corp. | 29.20 | -10.45 | -26.36% | |
| TW:1295 | Synbio Tech Inc | 41.80 | -54.05 | -56.39% | |
| TW:4911 | G&E Herbal Biotechnology Co., Ltd. | 25.30 | -18.34 | -42.03% | |
| TW:6808 | 3D Global Biotech Inc. | 26.00 | -19.95 | -43.42% | |
| TW:6986 | HeXun Biosciences Co Ltd | 37.30 | -23.42 | -38.57% | |
| TW:7507 | Enrestec, Inc. | 19.20 | -22.50 | -53.96% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026